In order to deeply implement the CPC Central Committee, the State Council and the provincial party committee, the provincial government's relevant decision-making and deployment, to promote the biomedical industry chain open innovation, to seize the commanding heights of the development of the global biomedical industry, is to promote the province's high-quality development of the biomedical industry put forward the following policy measures.

One, further clarify the development goals and requirements

1 ﹒ Goal requirements. Adhere to the guidance of Xi Jinping's thought of socialism with Chinese characteristics in the new era, thoroughly implement the spirit of the Fifth Plenary Session of the 19th CPC Central Committee and the important instructions of General Secretary Xi Jinping on the work of Jiangsu, compare with the international development trend, based on the basis of Jiangsu's development, adhere to the principles of innovation-driven, problem-oriented, enterprise-oriented, and industry chain layout, and accelerate the construction of a biomedical industry chain supply chain with stronger innovation, higher value-added, safer and more reliable. supply chain of biomedical industry chain. By 2024, the basic capability and industry chain modernization level of the province's biomedical industry will be continuously improved, the scale of industrial development will maintain a leading position in the country, the proportion of innovative drugs and high-end medical devices with independent intellectual property rights will be significantly increased, a number of key core technologies restricting the high-quality development of the biomedical industry will be tackled, a number of world-class biomedical enterprises will be constructed, a number of top scientific and technological talents and teams will be gathered, and a number of core competitive biomedical enterprises will be formed. A number of core competitiveness of the biomedical industry cluster and specialized parks, to create a leading national and globally influential biomedical industry cluster.

2. Enhance the ability of original innovation and key core technologies

2. Build a national biopharmaceutical technology innovation center at a high level. Adhere to the "four directions", accurately grasp the function and positioning, strengthen demand-oriented and problem-oriented, gather global innovation resources, innovate the R&D system and mechanism, focus on overcoming a number of key core technologies, cultivate and grow a number of innovative leading enterprises, promote the transformation of a number of leading, leading and permeable major scientific and technological achievements, and promote the deep integration of the innovation chain and the industrial chain, as well as the construction of the National Biopharmaceutical Technology Innovation Center. The innovation chain and industrial chain will be deeply integrated to seize the high point of global technology and industry, and create a strategic scientific and technological force in the field of biomedicine in China. The province and city will provide support and guarantee in terms of infrastructure, capital investment, innovation environment, etc., and give support to the construction of major projects and introduction of key talents and teams in the innovation center according to the principle of "one issue at a time". [Responsible units: Provincial Science and Technology Department, Provincial Party Committee Organization Department (Provincial Talent Office), Provincial Development and Reform Commission, Provincial Department of Finance, etc., Suzhou and other relevant local governments]

3. Accelerate the construction of major innovation platforms. For new targets, new structures, new forms of biomedical R & D innovation needs, focusing on genomics, proteomics, metabolomics, translational medicine, precision therapy and other key areas, to support colleges and universities, medical institutions and backbone enterprises to build a number of major innovation platforms, approved to be included in the sequence of the national scientific and technological innovation bases, to take the "one case at a time" way to give key support. For those approved to be included in the sequence of national science and technology innovation bases, "one case, one proposal" will be adopted to give key support. Support Suzhou to create a national biomacromolecule drug industry innovation center, efforts to strive for more related areas of technological innovation centers, industrial innovation centers, engineering research centers, manufacturing innovation centers and other state-level platforms to land in our province, and accelerate the construction of provincial technological innovation centers, industrial innovation centers, engineering research centers, manufacturing innovation centers and other innovation platforms carrier. (Responsible units: Provincial Department of Science and Technology, Provincial Development and Reform Commission, Provincial Department of Industry and Information Technology, Provincial Department of Finance, Provincial Health Commission, etc.)

4. Strengthening the original innovation and the bottom of the basic technological breakthroughs. The company has been studying major scientific frontiers or major industrial forward-looking issues in the field of biomedicine, aiming at the discovery of new drug targets, cell therapy drug design, formulation theory, molecular imaging, surgical robotics and other frontiers, exploring the use of "unveiling the list of commanders", directional commissioning and other ways to select leading scientists, granting full scientific research autonomy, and organizing original research and underlying basic technology breakthroughs. Organize to carry out original research and underlying basic technology research, in line with the conditions of the province's cutting-edge leading technology basic research special projects to give 5 million yuan -20 million yuan of financial support. (Responsible unit: Provincial Science and Technology Department, etc.)

5. Support the research and development of innovative drugs and medical devices. Registered in our province independent legal person enterprise completed phase II clinical research and has started phase III clinical trials of innovative drugs, has completed prototype (samples) test medical devices (need to be clinically has started the study) and other industrialization projects, merit to give 10 million yuan -30 million yuan of financial support. For innovative drugs (drug registration classified as Class 1 for Chinese medicine, Class 1 for chemical medicine, and Class 1 for biological products) that have completed Phase I, II and III clinical trials, as well as those that have been licensed by the applicants registered in our province and are manufactured in our province, a maximum of RMB 30 million will be given according to the different stages of research and development on the basis of merit. For improved new drugs (drug registration classified as Class 2 for traditional Chinese medicine, Class 2 for chemical drugs and Class 2 for biological products) that have completed Phase II and Phase III clinical trials, as well as those that have been licensed by the applicant for registration in our province and are manufactured in our province, a maximum of 10 million RMB will be provided according to different stages of research and development on the basis of merit. For medical device products entering the special review procedures for innovative medical devices of the state and the province, the maximum financial support of 2 million yuan will be given on merit, and for medical device products entering the above procedures, obtaining the certificate of registration of medical devices for the first time (Class III) and produced in the province, the maximum financial support of 20 million yuan will be given on merit. The cumulative amount of support for each unit shall not exceed 100 million yuan per year. (Responsible units: Provincial Science and Technology Department, Provincial Department of Finance, etc.)

6. Promote the construction of clinical research support platform. Integrate biological sample libraries and other medical information resources to establish an open and shared digital clinical research resource service platform. It will formulate grading and classification standards for the opening of health and healthcare big data, promote the construction of pilot provinces for national healthcare big data centers and industrial parks, and support the construction of healthcare big data centers in Nanjing and Changzhou, so as to realize the sharing of health and healthcare resources, cross-region collection, data exchange and scientific utilization. Layout and construction of high-level biosafety laboratories. (Responsible units: Provincial Health Commission, Provincial Development and Reform Commission, Provincial Drug Administration, Provincial Science and Technology Department, Provincial Department of Education, Provincial Department of Agriculture and Rural Affairs, etc.)

7. Strengthening of drug clinical research and transformation of results. Coordinate the province's clinical research resources, encourage medical institutions to carry out clinical research on new drugs, and incorporate clinical research into the performance assessment of medical institutions. For hospitals that have obtained the qualification of clinical trial organization, the number of beds that can be used for clinical research is not less than 30, increasing year by year in accordance with the ratio of not less than 30%, and by 2024, the number of clinical research beds will be increased to about 10% of the total number of beds in the hospital establishment. The recognized clinical research beds are not counted in the management of total hospital beds in medical institutions, and no assessment of bed efficiency, turnover rate and utilization rate is made. When the total number of personnel is approved, increase the number of authorized clinical research personnel positions. Clinical trial projects will be treated as scientific research projects, and will be used as an important basis for medical personnel's title evaluation, job promotion and performance appraisal. For medical personnel who have made major contributions to the transformation of clinical research results, the cash incentive for the transformation of scientific and technological achievements of their positions is allowed to be included in the total amount of performance pay for that year, without being limited by the total amount and not included in the total amount of the base. Explore the establishment of provincial clinical research ethics committees, ethical review regional alliances, etc., establish ethical collaborative review mechanisms, and gradually promote mutual recognition of ethical review results. (Responsible units: Provincial Health Commission, Provincial Drug Administration, Provincial Department of Human Resources and Social Security, Provincial Department of Science and Technology, etc.)

8. Enhancement of the innovation capacity of the integration of industry and medicine. Encourage relying on the conditions of medical and health institutions to build "production, medical research and use" integration of research hospitals or model research wards. Supporting research hospitals to carry out self-made in vitro diagnostic reagents pilot and expanding sympathetic use of clinical trials with drugs. Support universities, institutes, medical and health institutions and social forces to build a technology transfer platform such as the Institute of Translational Medicine. Support medical institutions to explore the establishment of scientific and technological achievements (intellectual property/intangible assets) operating companies. (Responsible units: Provincial Health Commission, Provincial Drug Administration, Provincial Department of Science and Technology, etc., the municipal governments)

Three, optimize the review and approval of drug and medical device services

9. Accelerate the listing review and approval. Optimize the review and approval process of Class II medical devices, establish and improve the road classification, segmentation and hierarchical review mechanism, and further compress the review and approval time frame. The establishment of innovative medical devices priority review and approval channel, the implementation of priority testing, priority review, priority inspection, priority approval. For the imported medical device products that have obtained the certificate of registration in China to apply for product registration in our province, optimize the relevant registration declaration information requirements. The implementation of mutual recognition of inspection results system, the orderly merger of drug registration, production licensing and other on-site inspections, reduce the frequency of on-site inspections. (Responsible unit: Provincial Drug Administration, etc.)

10. Promote the innovation of market supervision mechanism. The implementation of drug listing license holders, medical device registrants production quality and safety responsibility list, the implementation of the main responsibility of enterprises. Promote the construction of electronic traceability system, strengthen the adverse drug reaction monitoring and evaluation system and capacity building. Building a digital regulatory platform for drugs and medical devices to enhance regulatory efficiency. Encourage enterprises to use the drug listing license holder system and medical device registrant system to optimize resource allocation and adjust the industrial layout of group companies. Standardize the access standards of the drug distribution industry and expand new modes and formats of online sales of drugs. Encourage the innovation of drug circulation model within the medical association, and improve the provisions of transferring clinically needed drugs and specialized preparations. (Responsible units: Provincial Bureau of Drug Administration, Provincial Department of Commerce, Provincial Health Commission, etc.)

11. Provide technical support for review and approval. Improve the working mechanism of research and review linkage, establish a system of pre-review of technical information, optimize communication methods and channels, carry out review according to the risk classification of products, and improve the efficiency of enterprise registration and declaration. Expand regulatory resources in various aspects, optimize the setup of technical support institutions through the establishment of review and inspection branches and other ways to enrich the professional and technical strength. Encourage third-party organizations to apply for national accreditation and undertake registration inspection tasks. Innovative inspector management mechanism, increase the government's efforts to purchase inspection services, and encourage municipalities to build and share inspector teams. Actively undertake national verification tasks, take the initiative to integrate into the State Drug Administration drugs, medical devices review and inspection of the Yangtze River Delta sub-center construction work, promote the sharing of inspection resources, information sharing, mutual recognition of results within the region, and promote the products to market as soon as possible. (Responsible units: Provincial Drug Administration, Provincial Department of Human Resources and Social Security, Provincial Party Committee and Editorial Office, etc.)

Four, improve the stability and competitiveness of the industrial chain supply chain

12. Strengthening of the key materials supply security. For biomedical key raw materials, high-end auxiliary materials, important consumables and other market demand, select the conditions of the region, the layout of the construction of biomedical key materials, green and efficient production bases, to take a special safety evaluation, special environmental impact assessment, special drug trial services, special supervision and other working mechanisms, for biomedical enterprises to provide small batch, low-cost, customized supply of key materials. (Responsible units: Provincial Department of Science and Technology, Provincial Department of Industry and Information Technology, Provincial Department of Ecology and Environment, Provincial Department of Emergency Response, Provincial Bureau of Pharmaceutical Administration, etc.)

13. Enhance the level of high-standardized large-scale production. Promote the study of drug continuous manufacturing review standards, promote technology application demonstration, encourage micro-reactors and other green, miniaturized production equipment and process development. Support qualified Chinese medicine manufacturers to strengthen scientific research, production and clinical use of Chinese medicine formula particles, and encourage the construction of Chinese medicine standardization system. Support enterprises to implement technological transformation around the direction of high-end, intelligent, green and service-oriented, and provide up to 40 million yuan of financial support to eligible ones. Support biomedical enterprises to technical maturation, pilot test evidence, mass production and other engineering stage of technical bottlenecks continue to tackle, to meet the conditions of up to 30 million yuan of financial support. Encourage localities to support the development of pharmaceutical contract manufacturing organization (CMO) or contract research and development production organization (CDMO) and other services to enhance the production service capacity. Major projects will be supported in accordance with the relevant provisions of the Jiangsu Provincial Strategic Emerging Industries Development Special Funds Management Measures. Support important APIs and high-end biomedical intermediates, etc. included in the provincial advanced manufacturing clusters of short-board technology products "neck" list of projects, the investment amount of its new projects may not be subject to the limitations of 1 billion access threshold. (Responsible units: Provincial Department of Industry and Information Technology, Provincial Department of Ecology and Environment, Provincial Emergency Department, Provincial Drug Administration, Provincial Development and Reform Commission, Provincial Department of Science and Technology, Provincial Bureau of Traditional Chinese Medicine, etc.)

14﹒ Optimize the management of biomedical environmental access. For qualified biomedical specialty parks, accelerate the linkage of planning EIA and project EIA, and simplify the EIA handling process. Provincial major industrial projects enjoy green approval channels, and the total pollutant emission targets can be coordinated and transferred within the municipalities under the premise of meeting the conditions of concession. For professional organizations dealing with hazardous waste in biomedical parks, the cities in the districts are encouraged to subsidize the disposal of hazardous waste in accordance with the amount of hazardous waste. (Responsible units: Provincial Department of Ecology and Environment, Provincial Development and Reform Commission, Provincial Department of Industry and Information Technology, Provincial Drug Administration, etc., the municipal governments)

15. Cultivate and grow innovative leading enterprises. Support leading enterprises to strengthen capital operation and grow bigger and stronger. Support leading enterprises to lead the formation of innovation consortium, promote the upstream and downstream of the industrial chain, large and medium-sized enterprises to integrate innovation. Strengthen investment attraction, support and encourage global benchmark biomedical enterprises to set up regional headquarters, R&D centers and production bases in Jiangsu. Support the construction of a one-stop innovation service platform covering the entire biomedical industry chain, vigorously develop biomedical professional service institutions and organizations, and implement "housekeeping" personalized services and precise support for various types of enterprises. Encourage biomedical enterprises to benchmark with international advanced level, formulate and implement advanced standards. Support the innovative development of supply chain service enterprises in the field of biomedicine. (Responsible units: the Provincial Department of Science and Technology, the Provincial Department of Industry and Information Technology, the Provincial Drug Administration, the Provincial Development and Reform Commission, the Provincial Department of Commerce, the Provincial Supervision and Regulation Bureau, etc.)

Fifth, to accelerate the application and promotion of innovative products in the pharmaceutical industry

16. Support innovative products to speed up listing on the Internet. Support innovative products to speed up the listing on the Internet. Open innovative products listed on the green channel, optimize the process of listing, in accordance with the price of enterprise declaration directly listed for the province's medical institutions to purchase and use, to promote innovation as soon as possible into clinical applications. For the inclusion of national innovative medical devices special review procedures or leading technology and have significant clinical application value of medical devices, optimize the audit process, to promote the listing on the market. (Responsible units: Provincial Medical Insurance Bureau, Provincial Drug Administration, etc.)

17. Support the use of innovative medicines into medical insurance. Actively recommend the province's pharmaceutical enterprises innovative products into the national health insurance drug catalog, to promote the transformation of innovative drug results, and promote the innovative development of the pharmaceutical industry. Establishing a fair and unified mechanism for guaranteeing the use of nationally negotiated medicines, and further opening up the "last kilometer" of nationally negotiated medicines by improving outpatient guarantee policies, unimpeded medication guarantee channels, reasonably adjusting the total amount of control, and upgrading the level of fine management of medical insurance. Eligible diagnostic and treatment programs and medical consumables will be included in the scope of medical insurance payment. Supporting localities to play the role of commercial insurance and other financial services, building a multi-level medical insurance system, enriching the supply of medical insurance products, and accelerating the benefits to more people in need. (Responsible units: Provincial Medical Insurance Bureau, Provincial Health Commission, Jiangsu Banking and Insurance Supervision Bureau, etc.)

18﹒Optimize the environment for the procurement and application of innovative products. Optimize the bidding and other procurement processes for innovative medicines, medical devices and consumables to enter hospitals, and urge and guide the medical institutions in the province to promptly include the products listed in the institutional procurement catalog. Establishing a green channel for the approval of nationally negotiated drugs to enter medical institutions, and equipping them according to the needs and procuring them as much as possible. Establish a meeting system for industry and information technology, medical insurance, health care, finance and other departments and medical institutions, develop and implement the first purchase of innovative products and first set of support policies, increase the first purchase of innovative products, and increase the share of government procurement. For the first unit of high-end medical devices and the first batch of new materials, eligible for financial support, up to 30 million yuan and 3 million yuan, respectively. Support the development of post-market re-evaluation of innovative products. Carry out the pilot of purchasing services for artificial intelligence-assisted diagnostic systems. (Responsible units: Provincial Health Insurance Bureau, Provincial Health Commission, Provincial Department of Industry and Information Technology, Provincial Drug Administration, Provincial Department of Finance, etc.)

19﹒ Establishment of decision-making advisory service mechanism. The establishment of Jiangsu Provincial Pharmaceutical Affairs Management and Pharmacotherapeutics Professional Committee to provide technical support and decision-making consulting for the province's medical institutions, such as pharmaceutical affairs management and pharmacy services. Instruct medical institutions above the second level to set up the management committee for clinical use of medical devices, and other medical institutions are equipped with special (part-time) personnel responsible for the management of clinical use of medical devices according to the actual situation of the institutions. (Responsible units: Provincial Health Commission, Provincial Drug Administration, Provincial Medical Insurance Bureau, etc.)

20 ﹒ Support innovative drugs to explore the international market. Support enterprises to apply for foreign registration and certification, guide the province's R & D and production of innovative drugs and high-end medical devices through the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), PMDA (Japan's Pharmaceuticals and Medical Devices Agency) or WHO (World Health Organization) and other international agencies to comply with the inspection, and in the relevant foreign markets to achieve sales. (Responsible units: the Provincial Drug Administration, the Commerce Department, etc.)

Sixth, to create a highland of biomedical innovation talent

21. Actively introduce high-level biomedical talent. Adhere to the "break the four only" and "set up a new standard" and promote the main evaluation of employers and market-oriented, socialized evaluation, the establishment of a scientific and reasonable talent evaluation mechanism. Support the introduction of world-class top talents and teams, simplify the procedures, one case, special treatment, up to 100 million yuan of project funding. For multinational pharmaceutical companies, famous medical institutions or clinical research institutions outside of the R & D personnel and technical management personnel to work in Jiangsu for more than three years, in accordance with the prescribed procedures, can directly declare the provincial high-level and urgently needed and shortage of talents in the assessment of senior titles identified, into the provincial "Double Creation Plan", the provincial science and technology programs and other support, and recommended to declare the relevant national programs. Declare relevant national programs. For those who have settled in biomedical enterprises, they are encouraged to be employed as special professors or special researchers in provincial universities and institutes. [Responsible units: Provincial Party Committee Organization Department (Provincial Talent Office), Provincial Department of Human Resources and Social Security, Provincial Department of Education, Provincial Department of Science and Technology, etc.]

22. Encourage young talents in the field of biomedicine to settle in the enterprise. Support the province's biomedical backbone enterprises to set up post-doctoral research stations, where the station work of the doctor, priority included in the post-doctoral funding program at all levels of funding objects. The postdoctoral station can directly declare the title of deputy high school, with the title of deputy high school can directly declare the title of full high school, the scientific research achievements during the station as an important basis for evaluation. Postdoctoral fellows who have been working in professional and technical positions for one year and have outstanding performance will be given priority to be promoted to higher titles under the same conditions. For those who come to work in Suzhou full-time and meet the conditions to be recognized as provincial "double-creative doctor", 150,000 yuan will be given as financial subsidies. [Responsible unit: Provincial Party Committee Organization Department (Provincial Talent Office), Provincial Human Resources and Social Security Department]

23. Introducing and cultivating scarce talents in the field of biomedicine. Encourage enterprises in the field of biomedicine, colleges and universities, research and development institutions, medical and health institutions to introduce pharmaceutical services, drug registration, new drug patents, pharmaceutical R & D data analysis and other areas of scarce talent, in the provincial "Double Creation Program" in the opening of a special reporting channels and give support to tilt, support the completion of the period after the assessment of excellence and meet the conditions, by recommending recognized as the provincial "Double Creation Program". Recommendation recognized as the provincial "333 Project" corresponding level of training objects. Increase the cultivation of highly skilled personnel in key manufacturing positions such as pharmaceutical production processes, inspection and testing, quality control, and support the construction of highly skilled personnel training demonstration bases in key biomedical enterprises, and encourage enterprises to adopt a new type of apprenticeship, modern apprenticeship "customized" training of talents, and to strengthen vocational education and training of skilled personnel. Support enterprises to cooperate with colleges and universities and medical institutions to build biomedical applied technology education and training bases, and incorporate relevant units into the scope of the construction of provincial professional and technical personnel continuing education bases. Support colleges and universities to strengthen the construction of life sciences, bioengineering, biomedical engineering and other disciplines, and promote the deepening of the connotation of the relevant disciplines to create first-class disciplines. [Responsible units: Provincial Party Committee Organization Department (Provincial Talent Office), Provincial Department of Human Resources and Social Security, Provincial Department of Science and Technology, Provincial Department of Education, Provincial Health Commission, etc.]

Seven, build a good ecology for the development of the biomedical industry

24. optimize the Optimize the regional layout of industrial development. Adhere to intensive development, innovative development, accelerate the construction of distinctive characteristics, complementary advantages, synergistic and orderly industrial innovation plateau, and strive to form a 100-billion biomedical industry clusters in Nanjing, Suzhou, Wuxi, Changzhou, Taizhou, Lianyungang and other places. Solidly promote the construction of industrial innovation belt along Shanghai and Nanjing, focusing on key areas of biomedicine, promoting the integration of the innovation chain and industrial chain layout, building an industrial development ecology, and creating a global landmark industry with international competitiveness. Support Jiangsu Pilot Free Trade Zone to accelerate the development of world-class biomedical industry clusters and innovation curators, system-based openness and industrial high-quality development of the first demonstration area. Support the construction of national strategic emerging industry cluster of biomedicine in Suzhou City, support Taizhou City to give full play to the effect of ministry-provincial co-construction mechanism, carry out the pilot development of large health industry cluster, build new vaccines and specific diagnostic reagents of national emerging industry cluster, and support Lianyungang to strive for the creation of the national innovation center of high-end preparations and green pharmaceutical manufacturing. The relevant cities and counties (cities and districts) that have taken the biomedical industry as a leading industry should formulate the development plan for the biomedical industry, and prioritize the support for incubators, crowdsource spaces, gas pedals, small and medium-sized enterprise public service demonstration platforms and other innovation and entrepreneurship carriers in the field of biomedicine. Encourage localities to organize high-level international exchange brand activities in the field of biomedicine. (Responsible units: Provincial Development and Reform Commission, Provincial Department of Science and Technology, Provincial Department of Industry and Information Technology, Provincial Bureau of Pharmaceutical Supervision, Provincial Department of Commerce, etc., the relevant local governments)

25. Support the whole industry chain to open up innovation. Support the Pilot Free Trade Zone engaged in pharmaceutical and biotechnology R & D, testing and other outsourcing services enterprises to declare technologically advanced service enterprises. Support the Pilot Free Trade Zone eligible biomedical industry projects into the province's major projects, project land into the industrial and productive R & D land security line range. Support Nanjing, Suzhou drug import port declaration of imported biological products customs clearance record and the first import of chemical drugs customs clearance record function. Support Lianyungang to declare drug import port. On the premise of conforming to the industrial function orientation and the dominant industrial use of the project, allow the transferee to independently determine the proportion of industrial use of the land on a pilot basis in the Pilot Free Trade Zone. Actively seek national support for Jiangsu Pilot Free Trade Zone to carry out early and pilot implementation in the construction of major innovation platforms, reform of the review and approval system for medicines and medical devices, expansion and opening up of the medical service industry, and drug regulatory capacity building. (Responsible units: Department of Commerce, Provincial Development and Reform Commission, Provincial Science and Technology Department, Provincial Taxation Bureau, Provincial Drug Administration, Provincial Department of Natural Resources, Nanjing Customs, etc.)

26. Supporting the Yangtze River Delta key technology joint research. Explore the establishment of the Yangtze River Delta joint research program to strengthen the "neck" and key core technologies in the field of biomedicine. Jointly carry out industrial chain complementary chain solid chain strong chain action, increase support for the Yangtze River Delta biomedical industry chain alliance, with leading enterprises as the core to promote in-depth cooperation between upstream and downstream enterprises. (Responsible units: Provincial Department of Industry and Information Technology, Provincial Department of Science and Technology, Provincial Development and Reform Commission, etc.)

27. Strengthen the collaborative protection of intellectual property rights. Promote Nanjing, Suzhou and other intellectual property protection center to speed up the construction, support Lianyungang to declare the construction of intellectual property protection centers for biomedical industry-related enterprises to provide rapid review of patents, rapid confirmation of rights, rapid rights protection "green channel". Strengthen the intellectual property rights protection and assistance for the biomedical industry, and provide professional advice and intellectual assistance relying on the resources of the expert think tank of the Jiangsu Branch of the National Overseas Intellectual Property Dispute Response Guidance Center. Take the biomedical industry as the key support field of the provincial high-value patent cultivation and upgrading project, support the leading and backbone enterprises, universities and institutes, intellectual property service organizations to jointly set up high-value patent cultivation demonstration centers, and reward the centers that have obvious results in cultivating high-value patents. (Responsible units: Provincial Intellectual Property Office and other relevant municipal governments)

28. Innovative pharmaceutical R & D results industrialization of financial services. Support the integration of advantageous resources between enterprises, mergers and reorganization, eligible for mergers and acquisitions of enterprises on the target enterprise's actual capital contribution (cash portion of the payment) of 5% of the subsidy, the maximum of not more than 30 million yuan. Actively explore new modes of biomedical financing such as intellectual property securitization. Supporting state-owned venture capital enterprises to adopt valuation in biomedical equity transactions after fulfilling standardized procedures, and supporting qualified managers to follow up on investment projects. Develop and design new financial products serving the biomedical industry. Support qualified biomedical enterprises in direct financing through IPO, bond issuance and other means. Encourage relevant insurance institutions to provide customized comprehensive insurance products such as liability insurance for human clinical trials of biopharmaceuticals, liability insurance for biopharmaceutical products, etc., and subsidize qualified biopharmaceutical institutions and enterprises according to 50% of the premiums actually paid by them, with the maximum of 500,000 yuan for a single policy, and the maximum annual subsidy for a single enterprise being not more than 5 million yuan. Give full play to the role of government investment funds and venture capital funds to support pharmaceutical research and development and industrialization of achievements. (Responsible units: Provincial Department of Industry and Information Technology, Provincial Intellectual Property Office, Provincial State-owned Assets Supervision and Administration Commission, Provincial Local Financial Supervision Bureau, Jiangsu Securities Regulatory Bureau, Jiangsu Banking Supervision and Administration Bureau, Provincial Department of Finance, Provincial Development and Reform Commission, etc.)

29. Improvement of the customs clearance mechanism for biomedical products. Establish a specialized directory of R&D, production, sales and other units involved in import and export business in the field of biomedicine, carry out credit cultivation, and provide customs clearance facilitation according to the credit rating. Upgrading the level of facilitation of government services in the Pilot Free Trade Zone, and piloting the approval of one-time import of control drugs for research purposes, the renewal of drug production/management licenses, and the issuance of business licenses for drug retail chain headquarters in the Pilot Free Trade Zone. Strengthen the import and export of drugs shore inspection function and service platform construction, for the province's pharmaceutical enterprises to participate in international R & D and trade to provide convenience. (Responsible units: Nanjing Customs, the Provincial Science and Technology Department, the Provincial Drug Administration, the Provincial Health Commission, the Provincial Department of Commerce, etc.)

30 ﹒ Improvement of the overall promotion and policy support mechanism. Establish a joint meeting system for the high-quality development of the provincial biomedical industry to study and formulate relevant policies, coordinate and resolve major issues, and promote the implementation of various goals and tasks. The joint meeting will be convened by the leaders of the provincial government, with the participation of responsible comrades from relevant departments and units of the province. Set up an expert advisory committee for the biomedical industry, responsible for strategic research, industrial analysis, technology forecasting and project consulting, etc., and provide opinions and suggestions for governmental decision-making. Implement the fair competition review system, increase the anti-monopoly and anti-unfair competition compliance guidance in the field of biomedicine, create a fair and competitive market environment, and stimulate corporate innovation and development momentum. Coordinate the existing provincial-level relevant special funds, increase financial support, broaden investment and financing channels, for the above policy measures in the local financial support projects have been implemented, the provincial-level relevant special to give preferential support, the subsidy ratio of no more than 50% of the local input, the formation of local-based, provincial and local linkage, encourage social capital investment in the financial support mechanism. (Responsible units: Provincial Department of Science and Technology, Provincial Development and Reform Commission, Provincial Department of Industry and Information Technology, Provincial Department of Finance, Provincial Health Commission, Provincial Health Insurance Bureau, Provincial Market Supervision Bureau, Provincial Local Financial Supervision Bureau, Jiangsu Banking and Insurance Supervision Bureau, etc., and the municipal governments of the districts)

These policies and measures shall be implemented from November 1, 2021, and shall be valid till December 31, 2024. If this policy measures and other similar policies in our province have duplication of views, in accordance with the "from the best, as high as possible, not repeated" principle to support.